Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106651 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 716
- Enrollment target
NCT01106651 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 716 participants.
The verdict
NCT01106651, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 716 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.
Interventions
- DRUG Placebo
- DRUG Canagliflozin 100 mg
- DRUG Canagliflozin 300 mg
- DRUG Antihyperglycemic agent(s)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 716 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01106651
The ClinicalTrials.gov registry entry for NCT01106651 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 716 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01106651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01106651 about?
NCT01106651 is a clinical study titled "A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.
What is the current status of trial NCT01106651?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 716 participants. The study started on 2010-06. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01106651?
The interventions under investigation include: Placebo (DRUG), Canagliflozin 100 mg (DRUG), Canagliflozin 300 mg (DRUG), Antihyperglycemic agent(s) (DRUG).
Who is sponsoring clinical trial NCT01106651?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.